Benitec Biopharma Ltd (BNTC)

Benitec Biopharma (BNTC) Income Statement


Benitec Biopharma Income Statement

Last quarter (Q3 2024), Benitec Biopharma's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q3, Benitec Biopharma's net income was $-4.28M. See Benitec Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 23Jun 22Jun 21Jun 20Jun 16
Total Revenue
$ 54.00K$ 75.00K$ 73.00K$ 59.00K$ 97.00K$ 346.51K
Cost of Revenue
$ 107.00K-$ 9.00K$ 123.00K$ -185.00K$ 103.80K
Gross Profit
$ 159.00K$ 75.00K$ 64.00K$ -64.00K$ 282.00K$ 242.70K
Operating Expense
$ 21.34M$ 19.16M$ 17.92M$ 13.53M$ 8.56M$ 16.20M
Operating Income
$ -21.28M$ -19.08M$ -17.85M$ -13.60M$ -8.28M$ -15.96M
Net Non Operating Interest Income Expense
$ -23.00K$ -33.00K$ -32.00K$ -6.00K$ 62.00K-
Other Income Expense
$ 55.00K$ -448.00K$ -322.00K$ -280.00K$ -55.00K$ -2.54M
Pretax Income
$ -21.64M$ -19.56M$ -18.21M$ -13.88M$ -8.27M$ -18.50M
Tax Provision
-----$ 0.00
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -21.43M$ -19.56M$ -18.21M$ -13.88M$ -8.27M$ -18.50M
Basic EPS
$ -7.20$ -14.12$ -2.23$ -3.23$ -8.10$ -2.61
Diluted EPS
$ -7.20$ -14.12$ -2.23$ -3.23$ -8.10$ -2.61
Basic Average Shares
$ 35.33M$ 1.39M$ 8.17M$ 4.30M$ 1.02M$ 9.49M
Diluted Average Shares
$ 35.33M$ 1.39M$ 8.17M$ 4.30M$ 1.02M$ 9.49M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
-----$ 373.39K
Total Expenses
$ 21.34M$ 19.16M$ 17.93M$ 13.65M$ 8.38M$ 16.31M
Net Income From Continuing And Discontinued Operation
$ -21.43M$ -19.56M$ -18.21M$ -13.88M$ -8.27M$ -18.50M
Normalized Income
$ -7.71M$ -15.45M$ -17.96M$ -13.56M$ -8.19M$ -15.96M
Interest Expense
--$ 32.00K---
$ -21.42M$ -19.53M$ -18.18M$ -13.60M$ -8.28M$ -15.96M
$ -16.77M$ -19.15M$ -17.78M$ -13.17M$ -7.91M$ -15.74M
Currency in USD

Benitec Biopharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis